Enliven Therapeutics reported second quarter financial results for the period ended June 30, 2026. The company posted a net loss of $32.5 million and research and development expenses of $29.0 million. As of June 30, Enliven held $895.2 million in cash, cash equivalents, and marketable securities, providing a runway into 2030. Clinically, the company announced positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML), showing a 61% overall major molecular response rate at the 80 mg dose. Enliven reached alignment with the FDA on key Phase 3 trial design components and received Fast Track designation for ELVN-001. The company expects to initiate the ENABLE-2 Phase 3 trial in the second half of 2026. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics.

Enliven Therapeutics, Inc. entered into an underwriting agreement on June 11, 2026, to issue and sell 8,933,334 shares of common stock at $37.50 per share and 1,733,333 pre-funded warrants at $37.499 per warrant. The offering is expected to close on June 15, 2026, with expected net proceeds of approximately $376.0 million, potentially increasing to $432.4 million if underwriters exercise their option to purchase an additional 1,600,000 shares. Enliven Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer and other diseases.

Enliven Therapeutics, Inc. announced updated positive Phase 1 ENABLE clinical trial data for ELVN-001 in patients with chronic myeloid leukemia, showing a 54% major molecular response rate in the overall Phase 1b cohort and 61% in the 80 mg QD cohort. The FDA selected 80 mg QD as the recommended dose for the upcoming Phase 3 ENABLE-2 trial. Enliven Therapeutics, Inc. is a biotechnology company focused on developing therapeutic candidates for cancer patients.

Enliven Therapeutics, Inc. stockholders approved an amendment to its Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000 shares, effective June 9, 2026. The company also elected two Class III directors, Richard Fair and Lori Kunkel, M.D., and ratified the appointment of Deloitte & Touche LLP as its independent registered public accounting firm. Enliven Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.